GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma - 23/10/13
Doi : 10.1016/j.jaci.2013.08.024
Louise Hosking, BSc a 
, Eugene Bleecker, MD b, Soumitra Ghosh, MD, PhD c, Astrid Yeo, PhD a, Loretta Jacques, PhD d, Michael Mosteller, PhD e, Deborah Meyers, PhD b
, Eugene Bleecker, MD b, Soumitra Ghosh, MD, PhD c, Astrid Yeo, PhD a, Loretta Jacques, PhD d, Michael Mosteller, PhD e, Deborah Meyers, PhD b a Department of Projects Clinical Platforms and Sciences, GlaxoSmithKline Research and Development, Stevenage, United Kingdom
b Center for Human Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, NC
c Department of Projects Clinical Platforms and Sciences, GlaxoSmithKline Research and Development, Upper Merion, Philadelphia, Pa
d Medicines Development Centre Global Clinical, GlaxoSmithKline Research and Development, Stockley Park, United Kingdom
e Department of Projects Clinical Platforms and Sciences, GlaxoSmithKline Research and Development, Research Triangle Park, NC
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Wednesday 23 October 2013
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
| The clinical studies described in this article were funded by GlaxoSmithKline. E. Bleecker (grant no. U01 HL65899) and D. Meyers (grant no. RC2 HL101487) were funded by grants from the National Institutes of Health. |
|
| Disclosure of potential conflict of interest: L. Hosking, S. Ghosh, A. Yeo, L. Jacques, and M. Mosteller are employees of and hold stock in GlaxoSmithKline. E. Bleecker has received grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute, Aerovance, AstraZeneca, Boehringer-Ingelheim-Pfizer, Centocor, Cephalon, Ception, Forest, Genentech, GlaxoSmithKline, MedImmune, Novartis, and Sanofi-Aventis and has consultant arrangements with GlaxoSmithKline, Boehringer-Ingelheim-Pfizer, Forest, Novartis, Regeneron, and Sanofi-Aventis. D. Meyers has been supported by one or more grants from the NIH. The rest of the authors are employed by and own stock/stock options in GlaxoSmithKline. |
© 2013
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?